Chugai Pharmaceutical Co Ltd
TSE:4519

Watchlist Manager
Chugai Pharmaceutical Co Ltd Logo
Chugai Pharmaceutical Co Ltd
TSE:4519
Watchlist
Price: 6 920 JPY 0.55% Market Closed
Market Cap: 11.6T JPY
Have any thoughts about
Chugai Pharmaceutical Co Ltd?
Write Note
Chugai Pharmaceutical Co Ltd
/
Balance Sheet
/
Additional Paid In Capital

Chugai Pharmaceutical Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Chugai Pharmaceutical Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Chugai Pharmaceutical Co Ltd
TSE:4519
Additional Paid In Capital
¥69.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%
Takeda Pharmaceutical Co Ltd
TSE:4502
Additional Paid In Capital
¥1.7T
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
41%
Daiichi Sankyo Co Ltd
TSE:4568
Additional Paid In Capital
¥4B
CAGR 3-Years
N/A
CAGR 5-Years
-47%
CAGR 10-Years
-28%
Otsuka Holdings Co Ltd
TSE:4578
Additional Paid In Capital
¥504.5B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
S
Shionogi & Co Ltd
TSE:4507
Additional Paid In Capital
¥14.2B
CAGR 3-Years
-1%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Astellas Pharma Inc
TSE:4503
Additional Paid In Capital
¥183.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
0%
No Stocks Found

Chugai Pharmaceutical Co Ltd
Glance View

Market Cap
11.4T JPY
Industry
Pharmaceuticals
Economic Moat
Narrow

Chugai Pharmaceutical Co., Ltd., a pivotal player in the pharmaceutical industry, finds its roots deeply intertwined with innovations in biotechnology. Established in Tokyo, Chugai has carved out a niche by focusing on the development and distribution of prescription pharmaceuticals tailored to address some of the most challenging medical conditions. The company's collaboration with Roche, a global healthcare leader, has strategically positioned it within the Roche Group, allowing access to an expansive trove of research and development resources. This partnership amplifies Chugai's innovative efforts, particularly in biologics and oncology, where they develop antibodies and therapies that have been instrumental in advancing clinical treatments worldwide. The synergy of Chugai's science-driven approach, coupled with Roche's global reach, has fostered a dynamic research environment that continues to push the boundaries of medical treatment possibilities. Revenue streams for Chugai are primarily anchored in the research, development, and subsequent commercialization of novel pharmaceuticals. The company gains its financial strength through successful product launches, sustained sales of flagship products, and collaborative research agreements. Chugai's extensive pipeline, particularly in the fields of oncology, immunology, and renal diseases, reflects a strategic emphasis on addressing unmet medical needs, with a considerable portion of their earnings reinvested into further research. Additionally, strategically negotiated licensing agreements allow Chugai to bolster its financial health by sharing its innovations with other industry players, maximizing distribution channels while ensuring a steady cash influx. Through this intricate balance of innovation, strategic partnerships, and a robust commercial network, Chugai not only thrives within the competitive pharmaceutical landscape but also contributes significantly to the global healthcare ecosystem.

Intrinsic Value
4 526.93 JPY
Overvaluation 35%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Chugai Pharmaceutical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
69.5B JPY

Based on the financial report for Sep 30, 2024, Chugai Pharmaceutical Co Ltd's Additional Paid In Capital amounts to 69.5B JPY.

What is Chugai Pharmaceutical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
0%

Over the last year, the Additional Paid In Capital growth was 0%. The average annual Additional Paid In Capital growth rates for Chugai Pharmaceutical Co Ltd have been 1% over the past three years , 1% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.